nodes	percent_of_prediction	percent_of_DWPC	metapath
Balsalazide—PPARG—psoriasis	0.756	1	CbGaD
Balsalazide—PTGS2—Triamcinolone—psoriasis	0.0764	0.424	CbGbCtD
Balsalazide—PTGS2—Betamethasone—psoriasis	0.0655	0.364	CbGbCtD
Balsalazide—PTGS2—Dexamethasone—psoriasis	0.0381	0.212	CbGbCtD
Balsalazide—PPARG—dermis—psoriasis	0.0134	0.324	CbGeAlD
Balsalazide—PTGS2—skeletal joint—psoriasis	0.00592	0.143	CbGeAlD
Balsalazide—PTGS2—synovial membrane of synovial joint—psoriasis	0.00449	0.109	CbGeAlD
Balsalazide—PPARG—endothelium—psoriasis	0.00409	0.0989	CbGeAlD
Balsalazide—Olsalazine—IFNG—psoriasis	0.00302	0.47	CrCbGaD
Balsalazide—PTGS2—skin epidermis—psoriasis	0.00288	0.0697	CbGeAlD
Balsalazide—PTGS1—endothelium—psoriasis	0.00219	0.0529	CbGeAlD
Balsalazide—PTGS2—endothelium—psoriasis	0.00209	0.0506	CbGeAlD
Balsalazide—PPARG—skin of body—psoriasis	0.00175	0.0422	CbGeAlD
Balsalazide—Olsalazine—PPARG—psoriasis	0.00142	0.221	CrCbGaD
Balsalazide—PPARG—tendon—psoriasis	0.00133	0.0322	CbGeAlD
Balsalazide—Bezafibrate—PPARG—psoriasis	0.000995	0.155	CrCbGaD
Balsalazide—Sulfasalazine—PPARG—psoriasis	0.000986	0.154	CrCbGaD
Balsalazide—PTGS1—skin of body—psoriasis	0.000935	0.0226	CbGeAlD
Balsalazide—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000898	0.157	CbGdCrCtD
Balsalazide—PTGS2—skin of body—psoriasis	0.000893	0.0216	CbGeAlD
Balsalazide—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000719	0.126	CbGdCrCtD
Balsalazide—PTGS1—tendon—psoriasis	0.000711	0.0172	CbGeAlD
Balsalazide—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000699	0.122	CbGdCrCtD
Balsalazide—PTGS2—tendon—psoriasis	0.00068	0.0164	CbGeAlD
Balsalazide—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.000542	0.0948	CbGdCrCtD
Balsalazide—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000434	0.076	CbGdCrCtD
Balsalazide—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000434	0.076	CbGdCrCtD
Balsalazide—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000422	0.0738	CbGdCrCtD
Balsalazide—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000328	0.0574	CbGdCrCtD
Balsalazide—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000328	0.0574	CbGdCrCtD
Balsalazide—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.00032	0.0561	CbGdCrCtD
Balsalazide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	0.000317	0.0299	CbGpPWpGaD
Balsalazide—PTGS1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000316	0.0298	CbGpPWpGaD
Balsalazide—PPARG—Transcription factor regulation in adipogenesis—LEP—psoriasis	0.00029	0.0273	CbGpPWpGaD
Balsalazide—PPARG—Differentiation of white and brown adipocyte   —LEP—psoriasis	0.000262	0.0247	CbGpPWpGaD
Balsalazide—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000256	0.0241	CbGpPWpGaD
Balsalazide—PPARG—Nuclear Receptors—VDR—psoriasis	0.000234	0.022	CbGpPWpGaD
Balsalazide—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000234	0.022	CbGpPWpGaD
Balsalazide—PPARG—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.000223	0.021	CbGpPWpGaD
Balsalazide—ALOX5—Selenium Micronutrient Network—CAT—psoriasis	0.000199	0.0187	CbGpPWpGaD
Balsalazide—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000198	0.0346	CbGdCrCtD
Balsalazide—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000198	0.0346	CbGdCrCtD
Balsalazide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000194	0.0183	CbGpPWpGaD
Balsalazide—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.000193	0.0338	CbGdCrCtD
Balsalazide—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000185	0.0175	CbGpPWpGaD
Balsalazide—PPARG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000185	0.0174	CbGpPWpGaD
Balsalazide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000178	0.0168	CbGpPWpGaD
Balsalazide—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000168	0.0158	CbGpPWpGaD
Balsalazide—PPARG—PPARA activates gene expression—CARM1—psoriasis	0.000168	0.0158	CbGpPWpGaD
Balsalazide—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000164	0.0154	CbGpPWpGaD
Balsalazide—ALOX5—Selenium Micronutrient Network—CRP—psoriasis	0.000158	0.0149	CbGpPWpGaD
Balsalazide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000153	0.0144	CbGpPWpGaD
Balsalazide—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000152	0.0143	CbGpPWpGaD
Balsalazide—ALOX5—Selenium Micronutrient Network—ICAM1—psoriasis	0.000145	0.0137	CbGpPWpGaD
Balsalazide—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.000134	0.0126	CbGpPWpGaD
Balsalazide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000129	0.0121	CbGpPWpGaD
Balsalazide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000124	0.0117	CbGpPWpGaD
Balsalazide—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000121	0.0114	CbGpPWpGaD
Balsalazide—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000117	0.0111	CbGpPWpGaD
Balsalazide—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000113	0.0106	CbGpPWpGaD
Balsalazide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000112	0.0106	CbGpPWpGaD
Balsalazide—ALOX5—Selenium Micronutrient Network—IFNG—psoriasis	0.000111	0.0104	CbGpPWpGaD
Balsalazide—PPARG—Transcription factor regulation in adipogenesis—IL6—psoriasis	0.000108	0.0102	CbGpPWpGaD
Balsalazide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000108	0.0101	CbGpPWpGaD
Balsalazide—PPARG—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	0.000107	0.0101	CbGpPWpGaD
Balsalazide—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.000107	0.01	CbGpPWpGaD
Balsalazide—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000106	0.00996	CbGpPWpGaD
Balsalazide—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000104	0.00977	CbGpPWpGaD
Balsalazide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.0001	0.00942	CbGpPWpGaD
Balsalazide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	9.89e-05	0.00932	CbGpPWpGaD
Balsalazide—PTGS2—S1P1 pathway—VEGFA—psoriasis	9.79e-05	0.00922	CbGpPWpGaD
Balsalazide—PPARG—Adipogenesis—SOCS1—psoriasis	9.49e-05	0.00894	CbGpPWpGaD
Balsalazide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	9.3e-05	0.00875	CbGpPWpGaD
Balsalazide—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	9.25e-05	0.00871	CbGpPWpGaD
Balsalazide—ALOX5—Selenium Micronutrient Network—NFKB1—psoriasis	9.2e-05	0.00866	CbGpPWpGaD
Balsalazide—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	8.63e-05	0.00813	CbGpPWpGaD
Balsalazide—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	8.53e-05	0.00803	CbGpPWpGaD
Balsalazide—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	8.39e-05	0.0079	CbGpPWpGaD
Balsalazide—PPARG—Gene Expression—TARS—psoriasis	8.19e-05	0.00771	CbGpPWpGaD
Balsalazide—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	7.99e-05	0.00753	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism—NDUFA5—psoriasis	7.8e-05	0.00734	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.79e-05	0.00734	CbGpPWpGaD
Balsalazide—PPARG—Regulation of retinoblastoma protein—JUN—psoriasis	7.45e-05	0.00701	CbGpPWpGaD
Balsalazide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	7.29e-05	0.00686	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.27e-05	0.00685	CbGpPWpGaD
Balsalazide—ALOX5—Selenium Micronutrient Network—TNF—psoriasis	7.15e-05	0.00674	CbGpPWpGaD
Balsalazide—PPARG—Adipogenesis—LEP—psoriasis	7.01e-05	0.0066	CbGpPWpGaD
Balsalazide—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	6.96e-05	0.00655	CbGpPWpGaD
Balsalazide—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	6.88e-05	0.00648	CbGpPWpGaD
Balsalazide—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	6.85e-05	0.00645	CbGpPWpGaD
Balsalazide—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	6.85e-05	0.00645	CbGpPWpGaD
Balsalazide—PPARG—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	6.84e-05	0.00644	CbGpPWpGaD
Balsalazide—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	6.77e-05	0.00638	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism—CYP2S1—psoriasis	6.63e-05	0.00624	CbGpPWpGaD
Balsalazide—PPARG—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	6.34e-05	0.00597	CbGpPWpGaD
Balsalazide—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	6.3e-05	0.00593	CbGpPWpGaD
Balsalazide—PPARG—Signaling events mediated by HDAC Class I—STAT3—psoriasis	6.14e-05	0.00579	CbGpPWpGaD
Balsalazide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	5.98e-05	0.00563	CbGpPWpGaD
Balsalazide—ALOX5—Selenium Micronutrient Network—IL6—psoriasis	5.77e-05	0.00544	CbGpPWpGaD
Balsalazide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	5.56e-05	0.00524	CbGpPWpGaD
Balsalazide—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	5.44e-05	0.00512	CbGpPWpGaD
Balsalazide—PPARG—Generic Transcription Pathway—CARM1—psoriasis	5.35e-05	0.00504	CbGpPWpGaD
Balsalazide—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	5.32e-05	0.00501	CbGpPWpGaD
Balsalazide—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriasis	5.32e-05	0.00501	CbGpPWpGaD
Balsalazide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	5.17e-05	0.00487	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—CARM1—psoriasis	5.04e-05	0.00474	CbGpPWpGaD
Balsalazide—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	5e-05	0.00471	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—IL4—psoriasis	4.98e-05	0.00469	CbGpPWpGaD
Balsalazide—PPARG—Circadian rythm related genes—LEP—psoriasis	4.94e-05	0.00466	CbGpPWpGaD
Balsalazide—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	4.93e-05	0.00464	CbGpPWpGaD
Balsalazide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	4.83e-05	0.00455	CbGpPWpGaD
Balsalazide—PPARG—Metabolism—NDUFA5—psoriasis	4.83e-05	0.00454	CbGpPWpGaD
Balsalazide—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	4.79e-05	0.00451	CbGpPWpGaD
Balsalazide—PPARG—Circadian rythm related genes—NOS2—psoriasis	4.61e-05	0.00434	CbGpPWpGaD
Balsalazide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	4.54e-05	0.00427	CbGpPWpGaD
Balsalazide—PPARG—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.5e-05	0.00424	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—LEP—psoriasis	4.21e-05	0.00396	CbGpPWpGaD
Balsalazide—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	4.14e-05	0.0039	CbGpPWpGaD
Balsalazide—PPARG—Metabolism—CYP2S1—psoriasis	4.1e-05	0.00386	CbGpPWpGaD
Balsalazide—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	3.99e-05	0.00376	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	3.95e-05	0.00372	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—NOS2—psoriasis	3.92e-05	0.00369	CbGpPWpGaD
Balsalazide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	3.87e-05	0.00364	CbGpPWpGaD
Balsalazide—PTGS2—C-MYB transcription factor network—CD4—psoriasis	3.81e-05	0.00359	CbGpPWpGaD
Balsalazide—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	3.81e-05	0.00358	CbGpPWpGaD
Balsalazide—PPARG—Adipogenesis—STAT3—psoriasis	3.74e-05	0.00353	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.47e-05	0.00327	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism—NDUFA5—psoriasis	3.38e-05	0.00318	CbGpPWpGaD
Balsalazide—PPARG—Adipogenesis—TNF—psoriasis	3.24e-05	0.00305	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism—CARM1—psoriasis	3.24e-05	0.00305	CbGpPWpGaD
Balsalazide—PPARG—Generic Transcription Pathway—VDR—psoriasis	3.2e-05	0.00301	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.18e-05	0.00299	CbGpPWpGaD
Balsalazide—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	3.17e-05	0.00298	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	3.15e-05	0.00297	CbGpPWpGaD
Balsalazide—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	3.1e-05	0.00292	CbGpPWpGaD
Balsalazide—PPARG—Circadian rythm related genes—JUN—psoriasis	3.05e-05	0.00288	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.03e-05	0.00285	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—IFNG—psoriasis	3.01e-05	0.00283	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism—CYP2S1—psoriasis	2.87e-05	0.00271	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	2.8e-05	0.00263	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism—NDUFA5—psoriasis	2.68e-05	0.00253	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.67e-05	0.00251	CbGpPWpGaD
Balsalazide—PPARG—Adipogenesis—IL6—psoriasis	2.62e-05	0.00246	CbGpPWpGaD
Balsalazide—PPARG—Gene Expression—CARM1—psoriasis	2.58e-05	0.00243	CbGpPWpGaD
Balsalazide—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	2.5e-05	0.00236	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.5e-05	0.00236	CbGpPWpGaD
Balsalazide—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	2.46e-05	0.00232	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—LEP—psoriasis	2.41e-05	0.00227	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism—CYP2S1—psoriasis	2.28e-05	0.00215	CbGpPWpGaD
Balsalazide—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.15e-05	0.00202	CbGpPWpGaD
Balsalazide—PPARG—Circadian rythm related genes—TP53—psoriasis	2.02e-05	0.0019	CbGpPWpGaD
Balsalazide—PPARG—Metabolism—CARM1—psoriasis	2e-05	0.00189	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism—CAT—psoriasis	1.99e-05	0.00188	CbGpPWpGaD
Balsalazide—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	1.99e-05	0.00187	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—TNF—psoriasis	1.95e-05	0.00183	CbGpPWpGaD
Balsalazide—PPARG—Circadian rythm related genes—IL6—psoriasis	1.85e-05	0.00174	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—TYK2—psoriasis	1.84e-05	0.00173	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.77e-05	0.00167	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—TP53—psoriasis	1.72e-05	0.00162	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.7e-05	0.0016	CbGpPWpGaD
Balsalazide—PTGS2—Spinal Cord Injury—IL6—psoriasis	1.57e-05	0.00148	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism—APOE—psoriasis	1.55e-05	0.00146	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.55e-05	0.00146	CbGpPWpGaD
Balsalazide—PPARG—Gene Expression—VDR—psoriasis	1.54e-05	0.00145	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.51e-05	0.00142	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—NFKB1—psoriasis	1.43e-05	0.00135	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism—CARM1—psoriasis	1.4e-05	0.00132	CbGpPWpGaD
Balsalazide—ALOX5—Metabolism—PPARG—psoriasis	1.35e-05	0.00127	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.32e-05	0.00125	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.31e-05	0.00124	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—VEGFA—psoriasis	1.3e-05	0.00122	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—STAT3—psoriasis	1.29e-05	0.00121	CbGpPWpGaD
Balsalazide—PPARG—Metabolism—CAT—psoriasis	1.23e-05	0.00116	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.2e-05	0.00113	CbGpPWpGaD
Balsalazide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.17e-05	0.0011	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism—CARM1—psoriasis	1.11e-05	0.00105	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—TNF—psoriasis	1.11e-05	0.00105	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000981	CbGpPWpGaD
Balsalazide—PPARG—Metabolism—APOE—psoriasis	9.58e-06	0.000902	CbGpPWpGaD
Balsalazide—PPARG—Developmental Biology—IL6—psoriasis	8.99e-06	0.000846	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism—CAT—psoriasis	8.64e-06	0.000813	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism—CAT—psoriasis	6.86e-06	0.000645	CbGpPWpGaD
Balsalazide—PTGS2—Disease—HLA-A—psoriasis	6.81e-06	0.000641	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism—APOE—psoriasis	6.71e-06	0.000632	CbGpPWpGaD
Balsalazide—PTGS2—Disease—APOE—psoriasis	6.36e-06	0.000599	CbGpPWpGaD
Balsalazide—PTGS2—Disease—NOS2—psoriasis	5.93e-06	0.000558	CbGpPWpGaD
Balsalazide—PTGS1—Metabolism—PPARG—psoriasis	5.84e-06	0.00055	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism—APOE—psoriasis	5.33e-06	0.000502	CbGpPWpGaD
Balsalazide—PTGS2—Disease—TYK2—psoriasis	4.85e-06	0.000457	CbGpPWpGaD
Balsalazide—PTGS2—Metabolism—PPARG—psoriasis	4.64e-06	0.000437	CbGpPWpGaD
Balsalazide—PTGS2—Disease—CD4—psoriasis	4.39e-06	0.000413	CbGpPWpGaD
Balsalazide—PTGS2—Disease—STAT3—psoriasis	3.4e-06	0.00032	CbGpPWpGaD
Balsalazide—PTGS2—Disease—IL6—psoriasis	2.37e-06	0.000224	CbGpPWpGaD
